Clinical Trials Logo
  1. Home
  2. Neuroendocrine Carcinoma
  3. NCT06372626

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma Clinical Trial

Official title:
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Clinical Trial Summary

The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06372626
Study type Interventional
Source Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Contact Cheng Wei
Phone +8651257309965
Email weic@zelgen.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date August 2024
Completion date August 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT01642251 - Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT04069299 - Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
Recruiting NCT04464122 - Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Recruiting NCT04325425 - Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary Phase 2
Completed NCT03834701 - Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms N/A
Recruiting NCT03279614 - Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma Phase 2
Recruiting NCT05978284 - Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma Phase 1/Phase 2
Recruiting NCT05076786 - Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma Phase 2
Completed NCT00388063 - Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Phase 2
Withdrawn NCT03901378 - Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Phase 2
Recruiting NCT02970786 - Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans Phase 1
Completed NCT00663429 - Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma Phase 2
Recruiting NCT05113355 - Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm Phase 2
Completed NCT03278405 - Avelumab in G3 NEC Phase 1/Phase 2
Active, not recruiting NCT03837977 - Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma Phase 2
Not yet recruiting NCT06333314 - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Phase 2
Active, not recruiting NCT02687958 - Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Phase 2
Completed NCT01121939 - Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Phase 2
Recruiting NCT03168607 - Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma Phase 2
Enrolling by invitation NCT05396118 - Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients Phase 2